Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 19, 706-717
Abstract
No abstract availableKeywords
Funding Information
- Technical University of Denmark
This publication has 37 references indexed in Scilit:
- RNA-Targeted TherapeuticsCell Metabolism, 2018
- Locked nucleic acid: modality, diversity, and drug discoveryDrug Discovery Today, 2018
- Chemical Modification Study of Antisense GapmersNucleic Acid Therapeutics, 2012
- Selection, Optimization, and Pharmacokinetic Properties of a Novel, Potent Antiviral Locked Nucleic Acid-Based Antisense Oligomer Targeting Hepatitis C Virus Internal Ribosome Entry SiteAntimicrobial Agents and Chemotherapy, 2011
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense DrugsJournal of Biological Chemistry, 2004
- Hit and lead generation: beyond high-throughput screeningNature Reviews Drug Discovery, 2003
- Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad BioactivityJournal of Chemical Information and Computer Sciences, 2003
- Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.Proceedings of the National Academy of Sciences, 1988
- Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences, 1978